Next Article in Journal
Discordant Predictions of Extraglandular Involvement in Primary Sjögren’s Syndrome According to the Anti-SSA/Ro60 Antibodies Detection Assay in a Cohort Study
Previous Article in Journal
Effect of Trabeculectomy on Mean and Centroid Surgically Induced Astigmatism
Article Menu

History of Heart Failure in Patients Hospitalized Due to COVID-19: Relevant Factor of In-Hospital Complications and All-Cause Mortality up to Six Months

Institute of Heart Diseases, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland
Institute of Heart Diseases, University Hospital, 50-556 Wroclaw, Poland
Biostatistics Group, Department of Genetics, Wroclaw University of Environmental and Life Sciences, 51-631 Wroclaw, Poland
Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, 50-367 Wroclaw, Poland
Clinical Department of Internal and Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-556 Wroclaw, Poland
Gerontology Unit, Public Health Department, Wroclaw Medical University, 51-618 Wroclaw, Poland
Department of Pharmaceutical Biochemistry, Division of Pharmaceutical Biochemistry, Wroclaw Medical University, 50-556 Wroclaw, Poland
Department of Nursing and Obstetrics, Division of Internal Medicine Nursing, Wroclaw Medical University, 51-618 Wroclaw, Poland
Clinical Department of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, 50-556 Wroclaw, Poland
Clinical Department of Paediatric Nephrology, Wroclaw Medical University, 50-556 Wroclaw, Poland
Department of Pharmaceutical Biochemistry, Wroclaw Medical University, 50-556 Wroclaw, Poland
Clinical Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, 50-369 Wroclaw, Poland
Clinical Department of Heart Transplantation and Mechanical Circulatory Support, Institute of Heart Disease, Wroclaw Medical University, 50-556 Wroclaw, Poland
Wroclaw Medical University Biobank, Wroclaw Medical University, 50-556 Wroclaw, Poland
Division of Basic Sciences, Faculty of Health Sciences, Wroclaw Medical University, 50-368 Wroclaw, Poland
Clinical Department of Emergency Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland
Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Juan F. Delgado Jiménez
J. Clin. Med. 2022, 11(1), 241;
Received: 28 November 2021 / Revised: 28 December 2021 / Accepted: 30 December 2021 / Published: 3 January 2022
(This article belongs to the Section Cardiology)


Background: Patients with heart failure (HF) are at high risk of unfavorable courses of COVID-19. The aim of this study was to evaluate characteristics and outcomes of COVID-19 patients with HF. Methods: Data of patients hospitalized in a tertiary hospital in Poland between March 2020 and May 2021 with laboratory-confirmed COVID-19 were analyzed. The study population was divided into a HF group (patients with a history of HF) and a non-HF group. Results: Out of 2184 patients (65 ± 13 years old, 50% male), 12% had a history of HF. Patients from the HF group were older, more often males, had more comorbidities, more often dyspnea, pulmonary and peripheral congestion, inflammation, and end-organ damage biomarkers. HF patients had longer and more complicated hospital stay, with more frequent acute HF development as compared with non-HF. They had significantly higher mortality assessed in hospital (35% vs. 12%) at three (53% vs. 22%) and six months (72% vs. 47%). Of 76 (4%) patients who developed acute HF, 71% died during hospitalization, 79% at three, and 87% at six months. Conclusions: The history of HF identifies patients with COVID-19 who are at high risk of in-hospital complications and mortality up to six months of follow-up.
Keywords: COVID-19; SARS-CoV-2; heart failure; morbidity; mortality; long-term outcome COVID-19; SARS-CoV-2; heart failure; morbidity; mortality; long-term outcome

1. Introduction

Heart failure (HF) is one of the most common causes of death worldwide [1]. Approximately 64.3 million people currently live with HF, and the prevalence is estimated at 1–2% of the adult population in developed countries [2,3]. According to the studies of the HF Working Group of the Polish Cardiac Society based on reports of the National Health Fund, about 1.2 million people suffer from HF and 140 thousand die every year in Poland [4]. Despite the decline in cardiovascular mortality in the last decades, the prognosis in HF remains still poor. Approximately 24% of patients die within one year of HF diagnosis [5]. In-hospital mortality during HF hospitalizations is also unacceptably high and varies from 12 to 19%, depending on consecutive years, gender, and age groups [6].
The outbreak of coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a global health crisis that resulted in almost 4.9 million deaths worldwide until October 2021, while more than 241 million people were infected, and these numbers are still growing [7]. The clinical course of the SARS-CoV-2 infection range from asymptomatic to critical presentation [8]. While the severe and critical represented 21% of COVID-19 patients, the in-hospital infection fatality rates vary from 11% to 31% [8,9,10]. Three and six months all-cause mortality in patients hospitalized with COVID-19 was estimated at 28% and 30%, respectively [11]. However, the overall mortality rate in the population is lower ranging 0.3–5% [8,12,13].
Numerous risk factors for severe disease and death have been described since the beginning of the pandemic, including age, gender, lifestyle, laboratory indications, complications, and comorbidities [14]. Older age is associated with the risk of unfavorable course of the disease. In the United States, deaths of patients aged 50 years and older account for >94% of the total deaths due to SARS-CoV-2 infection [15,16]. While gender does not affect the risk of infection, in males with COVID-19, poorer outcomes and more deaths are observed, independent of age [17].
Patients with HF are at especially high risk of morbidity and mortality from SARS-CoV-2 infection [18]. COVID-19 is associated with an immune response leading to systemic inflammation [19]. Increased metabolic demands related to severe inflammatory reaction result in cardiac injury and myocardial functional disorders [18]. Moreover, the volume overload secondary to acute kidney injury (observed in up to 30% of patients with COVID-19), symptomatic treatment, fluid administration can aggravate chronic HF as well [13,19,20]. As a result, COVID-19 can exacerbate a pre-existing HF or even cause it de novo [2].
Interestingly, the COVID-19 pandemic has significantly decreased the number of overall hospital admissions for HF [21,22,23]. While patients with HF less frequently self-referred to the hospital, the number of HF patients brought by an ambulance increased [21]. Moreover, during the pandemic, HF patients were less frequently admitted in New York Heart Association (NYHA) Class II compared with the pre-pandemic period [22].
The multicenter, international retrospective cohort study showed that COVID-19 patients with HF are at increased risk for in-hospital death and in-hospital worsening of HF or acute HF de novo, which further increases in-hospital mortality [24].
Despite intensive investigation of cardiovascular diseases in COVID-19, still, little is known about the long-term outcomes of HF patients hospitalized with COVID-19. The aim of this study was to evaluate clinical characteristics, in-hospital course, and posthospital outcomes of this group.

2. Materials and Methods

2.1. Study Population

The single-center retrospective cohort study included consecutive adult patients hospitalized in the University Hospital, Wroclaw, Poland between March 2020 and May 2021 with laboratory-confirmed COVID-19 defined as a positive result by polymerase chain reaction testing of a nasopharyngeal sample or a positive blood antigen test. The study population was divided into two subgroups:
HF group: Patients with a history of HF, diagnosed before hospitalization, ac-cording to the European Association of Cardiology (ESC) guidelines [25,26],
Non-HF group: Patients without previous diagnosis of HF.

2.2. End-Points of the Study and Clinical Follow-Up

The primary endpoint was all-cause mortality at three months.
The secondary endpoints were:
in-hospital mortality,
duration of hospitalization,
admission to intensive care unit (ICU),
the incidence of complications during hospitalization: shock, myocardial infarc-tion (diagnosed according to Fourth Universal Definition of Myocardial Infarction [27]), thromboembolic disease, stroke, acute HF,
all-cause mortality at six months.

2.3. Study Procedures

The demographic data, the information about medical history, previous medication, signs, symptoms at admission, laboratory tests, in-hospital clinical course were extracted from electronic medical records.
The following laboratory measurements were evaluated on admission: hematology: hemoglobin, leukocytes, lymphocytes, neutrophils; serum electrolytes: sodium, potassium; markers of infection: C-reactive protein (CRP), procalcitonin, interleukin-6 (IL-6), ferritin; renal and liver function tests: estimated glomerular filtration rate (eGFR), blood urea nitrogen (urea), uric acid, bilirubin, gamma-glutamyl transferase (GGTP), albumin; cardiac troponin I; plasma N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP).
Surviving patients were followed by telephone contact after three and six months. Information was obtained directly from patients, their relatives, or from the hospital system. Government General Registry Office data regarding death were used to complete follow-up.

2.4. Statistical Analysis

The categorical variables were expressed as a number of patients in a given categories (with a percentage). The intergroup differences in categorical variables were tested using the χ2 test. Continuous variables with a normal distribution were expressed as a mean ( x ¯ ) (with standard deviation (SD)). Continuous variables with a skewed distribution were described by median (m) (with an interquartile range (IQR)). These variables were ln-transformed in order to normalize their distribution, and ln-transformed values were used for further statistical analyses. The intergroup differences for continuous variables were tested using Student’s t test. The associations between the occurrence of acute HF and clinical and laboratory variables were tested using stepwise forward selection based on the Akaike criterion. In the results, we got the model with three independent variables (age, history of HF, and history of myocardial infarction). The associations between the clinical and laboratory variables and survival during 90 days in patients with COVID-19 were established using Cox proportional hazard regression model (both univariable and multivariable models). Variables that were statistically significant in the univariable model were included in the multivariable model. To estimate the effect of history of HF on in-hospital, 3-months, and 6-months mortality, Kaplan–Meier curves were constructed. Differences in survival rates were tested with the log-rank test. The p-value < 0.05 was considered statistically significant. Statistical analyses were performed using the R software version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) and STATISTICA 13 data analysis software system (StatSoft, Inc., Tulsa, OK, USA).

3. Results

3.1. Characteristic of Study Population and Difference between Patients with a History of HF and without HF

The study included 2184 patients with a mean age of 65 ± 13 years, 1082 (50%) were male. There were 255 (12%) patients with a history of HF. Patients from the HF group were older, more often males, and had more comorbidities than patients without a history of HF. Before hospitalization, HF patients were more frequently treated with recommended HF medication, as well as calcium channel blockers, alpha-adrenergic blockers, statins, antiplatelet drugs, anticoagulants, antidiabetics, inhaled β2-agonists, anticholinergic drugs, and hemodialysis (see Table 1).
Patients with a history of HF reported dyspnea and chest pain on admission more frequently and their physical examination revealed more abnormalities (lower oxygen saturation on room air, wheezing, pulmonary congestion, and peripheral edema than patients from the non-HF group (see Table 2).
Patients with a history of HF were characterized by higher levels of cardiac (NT-proBNP, troponin I) and inflammatory (leucocytes, procalcitonin, IL-6) biomarkers as well as higher potassium, urea, uric acid, bilirubin levels, and lower number of lymphocytes, hemoglobin concentration, and eGFR (see Table 3).

3.2. The Association of HF History with In-Hospital Course and Applied Treatment and Procedures during Hospitalization

There were no statistically significant differences between groups in relation to the number of patients admitted to ICU and ventilated mechanically. However, HF patients were characterized by longer hospitalization and more often worsened during treatment (43% vs. 24%, p < 0.001), including the development of shock, myocardial infarction (diagnosed according to Fourth Universal Definition of Myocardial Infarction [27]), and acute HF. These patients more often required passive oxygen therapy, noninvasive ventilation, use of catecholamines, loop diuretics, amiodarone, nitroglycerine, direct oral anticoagulants, acetylsalicylic acid, antibiotics, and interventions like coronary angiography, coronary revascularization, and hemodialysis (see Table 4).
The predictors of acute HF were higher age and history of HF (see Table 5). The multivariable model included variables with a p-value < 0.001 in the univariable model.

3.3. Outcome

There was high mortality in the studied population with 326/2184 (15%) deaths during hospitalization, 546/2184 (25%) after three months, and 578/1491 (26%) after six months from admission. We found a relationship between history of HF before hospitalization and mortality in COVID-19 patients in relation to all endpoints (see Figure 1 and Figure 2). The HF group had significantly higher mortality assessed in hospital: 89 (35%) vs. 237 (12%), 3-month mortality: 132 (53%) vs. 413 (22%) and 6-month mortality: 141 (72%) vs. 436 (47%), all p < 0.001.
After the adjustment of variables that appeared to be significant predictors in univariate Cox analysis, history of HF was revealed to be a predictor of higher risk for three months mortality (see Table 6 and Table 7).
Among patients with a history of HF, significantly higher risk of three-month death was noted in patients ≤ 70 years old and in women ≤ 70 years old when compared with non-HF group. There were no differences in mortality risk in patients with a history of HF divided according to gender (see Figure 3).
Patients who developed acute HF during hospitalization had extremely high mortality: 54/76 (71%) died during hospitalization, 60/76 (79%) at three, and 61/70 (87%) at six months. Analyzing HF-group with available left ventricular ejection fraction (LVEF) measurement (130/255 patients, 51%), the mean LVEF was 46% ± 16%. There were 70 (54%) patients with HF with preserved ejection fraction (HFpEF), 19 (15%) with HF with mildly reduced ejection fraction (HFmrEF) and 41 (32%) with HF with reduced ejection fraction (HFrEF). In a subgroup analysis, patients with HFrEF and HFmrEF had higher in-hospital, 3-, and 6-month mortality, compared to patients with HFpEF (see Table 8).
Similar findings are related to those patients that had to be taken to ICU as compared to those without ICU stay (see Table 9 and Table 10).

4. Discussion

Our study for the first time analyzed not only the in-hospital course but also long-term mortality in this group of patients. The presented study, performed among a large cohort of hospitalized patients with COVID-19, showed how history of HF affects the in-hospital course and especially long-term follow-up. One-third of HF patients died during hospitalization and the next one-third died after hospital discharge in the next three months.
Older age, gender, and comorbidities are well-known risk factors of severe course of COVID-19. Patients with HF are usually elderly, with multiple underlying medical conditions increasing their risk of complications and mortality after SARS-CoV-2 infection [28,29,30]. Especially cardiovascular diseases and their risk factors (e.g., hypertension, diabetes mellitus, atrial fibrillation, ischemic heart disease) are common among HF patients [31]. However, HF remains independently associated with in-hospital mortality [24]. In our multivariable analyses, history of HF increased the risk of primary endpoint incidence from 30% to 83%.
The human angiotensin converting enzyme 2 (ACE2) receptor is a gateway for SARS-CoV-2 to enter cells. In the heart, the ACE2 receptors can be found on the surface of cardiomyocytes, cardiac fibroblasts, and endothelia of coronary arteries [32]. Recent studies showed increased levels of ACE2 in patients with HF, especially males consistently with the increased severity of COVID-19 among men [32,33,34].
Myocardial damage in COVID-19 can be caused by endothelial dysfunction and systemic inflammatory response, leading to plaque instability and prothrombotic state (type 1 MI), as well as by mismatch between oxygen supply and/or demand related with respiratory failure (type 2 MI) [35,36,37,38]. However, the role of SARS-CoV-2 in the direct myocardial injury (“myocarditis-like” effect) is still to be determined [36].
As reported in our manuscript, patients with a history of HF were characterized by higher levels of cardiac (NT-proBNP, troponin I) biomarkers and more often developed myocardial infarction. MI was diagnosed according to the Fourth Universal Definition of Myocardial Infarction [27]. However, troponin elevation can also be observed in a high number of clinical conditions, e.g., HF and a septic state [36,39]. It should be emphasized that troponin levels are mostly influenced by baseline characteristics, such as pre-existing HF or coronary artery disease [36,37]. In the study of 355 patients hospitalized with COVID-19, the levels of troponin were significantly higher in the group of patients with chronic coronary syndromes (CCS). Nevertheless, over 89% of significant troponin elevations in our sample population were nonspecific troponin leaks while only 11% had actual non-ST elevation [37].
Therefore, cardiac biomarkers elevation in COVID-19 may be sometimes misleading. Although myocardial injury has been shown to be associated with worse outcomes in COVID-19, a recent study revealed that troponin elevation had a prognostic value in non-CCS patients, while it was not predictive of poor outcomes in patients with CCS [36,39] Further studies are necessary to determine the role of troponin elevation as a prognostic marker.
In our study, significantly more women and men died in the HF group, compared to those in the non-HF group, but it also showed that the ratio of deaths between women and men did not differ in both groups. It should be emphasized that a significantly higher proportion of deaths was in younger people and younger women in the HF group than in those without HF.
The renal impairment secondary to acute kidney injury is observed in up to 30% of patients with COVID-19 [13,20]. While cardiorenal syndrome is a spectrum of well-known disorders in HF, in our study, patients with HF had worse kidney function, but the presence of chronic kidney disease was not associated with the higher risk of acute HF [40]. In the multivariable model, the only risk factors for developing acute HF were more advanced age and a history of previous HF.
In-hospital mortality rate of HF patients hospitalized with COVID-19 presented in our study remains consistent with prior literature. A study based on the multicenter, multinational PCHF-COVICAV registry analyzed 1974 patients hospitalized with COVID-19, HF was present in 256 patients. 1282 (65%) of patients had cardiovascular disease and/or risk factors. In this study, in-hospital mortality in the HF group reached 36% [24].
Furthermore, in the retrospective analysis of 6439 patients hospitalized in New York with COVID-19, the group of patients with HF was smaller (n = 422; 7%). The most frequent comorbidities in the whole study group were hypertension (35%), obesity (28%), and diabetes mellitus (23%). Likewise, compared with patients without HF, those with a history of HF were older, had a higher prevalence of comorbidities, and were receiving a greater number of medications. While total mortality was 26%, the risk of mortality among patients with HF was significantly higher than in the group of patients without HF (40 vs. 25%) [41].
In the study of 3080 patients with confirmed COVID-19, a group of 152 (5%) had a previous history of HF. Similar to our study, patients with HF had more cardiovascular risk factors and comorbidities than patients without a history of HF, and the most common were hypertension (86%), dyslipidemia (75%), atrial fibrillation/flutter (52%), and diabetes (40%). The overall mortality rate was 21% and was significantly higher in patients with previous HF (49 vs. 19%) [42].
However, the aforementioned studies analyzed HF patients already hospitalized with COVID-19; therefore, a certain selection bias cannot be excluded. In the study of 31,051 ambulatory patients with COVID-19, 20% of them had pre-existing HF and those had a 30-day mortality and 30-day admission rate of 5% and 19%, respectively. The overall 30-day mortality and 30-day admission rates were 2% and 10%, respectively. Patients with HF had higher comorbidity burden than the group without HF—they were more likely to be smokers (29% vs. 13%), have hypertension (84% vs. 50%), diabetes (54% vs. 28%), myocardial infarction (44% vs. 120%), and atrial fibrillation (29% vs. 4%) [43]. Thus, the profile of comorbidities seems similar in the groups of hospitalized and ambulatory HF patients.
In our study group, the frequency of comorbidities was similar to that reported in the prior literature—the most common concomitant disorders were hypertension (84%), atrial fibrillation (53%), diabetes mellitus (48%), and chronic kidney disease (36%) [41,42]. However, the incidence of atrial fibrillation among hospitalized HF patients is much higher in our study than in ambulatory patients [43]. Contrarily, the prevalence of cardiovascular disease and/or risk factors as well as HF were higher in the PCHF-COVICAV registry [24].
Before the COVID-19 outbreak, the prognosis in HF was unsatisfactory with the one year-mortality of patients after HF diagnosis estimated at 24% [5]. In-hospital mortality varied from 12% to 19%, depending on the study [6]. As our study revealed, SARS-CoV-2 infection significantly worsens in-hospital course and long-term prognosis of HF patients with three-month mortality two times higher than in HF patients without COVID-19. In the study assessing long-term outcomes after HF hospitalization during the COVID-19 pandemic in the group without SARS-CoV-2 infection, the median follow-up was 622 days. The number of patients that died post-discharge for 2020 and 2019 cohorts was 172 (44%) and 321 (34%), respectively [44]. Interestingly, a recent study showed that during the COVID-19 outbreak, there was a significant decrease in acute admissions, including HF, to the cardiology and emergency departments. While the in-hospital mortality in 2020 and 2019 was similar (3.6% vs. 3.9%, respectively), the death rates of patients admitted to emergency departments were four times higher [23].


Our study is limited by its retrospective, single-center character, which may limit its generalizability. Moreover, the study protocol did not include assessment of LVEF, and only small group of patients were evaluated with transthoracic echocardiography (TTE) due to safety reasons and from certain fraction of patients previous LVEF measurement was not available. Therefore, we are not able to stratify all HF population in relation to LVEF. Furthermore, the protocol of our study did not distinguish types of MI.
Thus, further prospective studies are required, not only to confirm the impact of SARS-CoV-2 infections on long-term outcomes of patients with HF but also to assess quality of medical care during COVID-19 pandemic. While the pathophysiology of COVID-19 and the risk of HF are still insufficiently understood, the impact of comorbidities on survival of patients with HF and COVID-19 should be also examined. Further analyses are needed in order to explain higher mortality among patients with HF, regardless of the presence of SARS-CoV-2 infection.

5. Conclusions

This retrospective study demonstrates high in-hospital mortality and poor long-term outcomes in patients with a history of HF hospitalized with COVID-19. The development of acute HF during hospitalization is associated with extremely high in-hospital and long-term mortality. Therefore, HF patients should be well and closely controlled; they should be treated both during hospitalization and afterward.

Author Contributions

Conceptualization, M.S., K.R., M.P., K.M. and E.A.J.; formal analysis, M.S. and T.S.; investigation, M.S., B.A., A.D., J.D., J.G.-D., M.J., K.K., K.K.-P., B.K., A.K., A.L., W.L., A.M.-W., L.P.-S., M.R.-B., J.M.S., J.S., A.Z.-T. and M.P.; methodology, M.S., T.S. and E.A.J.; project administration, M.S., M.P., K.M. and E.A.J.; supervision, M.P. and K.M.; visualization, M.S., T.S. and J.M.S.; writing—original draft, M.S., K.R., T.S., J.M.S. and E.A.J.; writing—review and editing, M.S., K.R., T.S., B.A., A.D., J.D., J.G.-D., M.J., K.K., K.K.-P., B.K., A.K., A.L., W.L., A.M.-W., L.P.-S., M.R.-B., J.M.S., J.S., A.Z.-T., M.P., K.M. and E.A.J. All authors have contributed substantially to this work. All authors have read and agreed to the published version of the manuscript.


The fundings from reserve of Rector for Scientific Affairs.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Bioethics Committee of Wroclaw Medical University, Wroclaw, Poland (Signature number: KB-444/2021).

Informed Consent Statement

The routine data were collected retrospectively; therefore, written informed consent to participate in the study was not required. The Bioethics Committee approved the publication of anonymized data.

Data Availability Statement

The data sets used and analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.


  1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1211–1259. [Google Scholar] [CrossRef]
  2. Groenewegen, A.; Rutten, F.H.; Mosterd, A.; Hoes, A.W. Epidemiology of heart failure. Eur. J. Heart Fail. 2020, 22, 1342–1356. [Google Scholar] [CrossRef]
  3. Benjamin, E.J.; Virani, S.S.; Callaway, C.W.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Chiuve, S.E.; Cushman, M.; Delling, F.N.; Deo, R.; et al. Heart Disease and Stroke Statistics—2018 Update: A Report from the American Heart Association. Circulation 2018, 137, e67–e492. [Google Scholar] [CrossRef]
  4. Nessler, J.; Siniarski, A.; Leszek, P.; Gumprecht, J.; Drożdż, J.; Kaźmierczak, J.; Witkowski, A.; Gackowski, A.; Jankowska, E.A.; Kukulski, T.; et al. Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiol. Pol. 2021, 79, 363–370. [Google Scholar] [CrossRef]
  5. Taylor, C.J.; Ordóñez-Mena, J.M.; Roalfe, A.K.; Lay-Flurrie, S.; Jones, N.; Marshall, T.; Hobbs, F.D.R. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: Population based cohort study. BMJ 2019, 364, l223. [Google Scholar] [CrossRef]
  6. Sierpiński, R.; Sokolska, J.M.; Suchocki, T.; Koń, B.; Urbański, F.; Kruk, M.; Sokolski, M.; Ponikowski, P.; Jankowska, E.A. 10 year trends in hospitalization rates due to heart failure and related in-hospital mortality in Poland (2010–2019). ESC Heart Fail. 2020, 7, 3365–3373. [Google Scholar] [CrossRef]
  7. World Health Organization. COVID-19 Explorer. Available online: (accessed on 21 October 2021).
  8. Jin, Y.; Yang, H.; Ji, W.; Wu, W.; Chen, S.; Zhang, W.; Duan, G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020, 12, 372. [Google Scholar] [CrossRef]
  9. Roth, G.A.; Emmons-Bell, S.; Alger, H.M.; Bradley, S.M.; Das, S.R.; de Lemos, J.A.; Gakidou, E.; Elkind, M.S.V.; Hay, S.; Hall, J.L.; et al. Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States during the COVID-19 Pandemic. JAMA Netw. Open 2021, 4, e218828. [Google Scholar] [CrossRef]
  10. Gray, W.K.; Navaratnam, A.V.; Day, J.; Babu, P.; Mackinnon, S.; Adelaja, I.; Bartlett-Pestell, S.; Moulton, C.; Mann, C.; Batchelor, A.; et al. Variability in COVID-19 in-hospital mortality rates between national health service trusts and regions in England: A national observational study for the Getting It Right First Time Programme. EClinicalMedicine 2021, 35, 100859. [Google Scholar] [CrossRef]
  11. Günster, C.; Busse, R.; Spoden, M.; Rombey, T.; Schillinger, G.; Hoffmann, W.; Weber-Carstens, S.; Schuppert, A.; Karagiannidis, C. 6-month mortality and readmissions of hospitalized COVID-19 patients: A nationwide cohort study of 8679 patients in Germany. PLoS ONE 2021, 16, e0255427. [Google Scholar] [CrossRef]
  12. Streeck, H.; Schulte, B.; Kümmerer, B.M.; Richter, E.; Höller, T.; Fuhrmann, C.; Bartok, E.; Dolscheid-Pommerich, R.; Berger, M.; Wessendorf, L.; et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nat. Commun. 2020, 11, 5829. [Google Scholar] [CrossRef]
  13. Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; Wu, Y.; Zhang, L.; Yu, Z.; Fang, M.; et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020, 8, 475–481. [Google Scholar] [CrossRef]
  14. Gao, Y.-D.; Ding, M.; Dong, X.; Zhang, J.-J.; Azkur, A.K.; Azkur, D.; Gan, H.; Sun, Y.-L.; Fu, W.; Li, W.; et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy 2021, 76, 428–455. [Google Scholar] [CrossRef]
  15. Centers for Disease Control and Prevention. Provisional COVID-19 Death Counts by Sex, Age, and State. Available online: (accessed on 21 October 2021).
  16. Pollard, C.A.; Morran, M.P.; Nestor-Kalinoski, A.L. The COVID-19 pandemic: A global health crisis. Physiol. Genom. 2020, 52, 549–557. [Google Scholar] [CrossRef]
  17. Jin, J.M.; Bai, P.; He, W.; Wu, F.; Liu, X.F.; Han, D.M.; Liu, S.; Yang, J.K. Gender Differences in Patients with COVID-19: Focus on Severity and Mortality. Front. Public Health 2020, 8, 152. [Google Scholar] [CrossRef]
  18. Bader, F.; Manla, Y.; Atallah, B.; Starling, R.C. Heart failure and COVID-19. Heart Fail. Rev. 2020, 26, 1–10. [Google Scholar] [CrossRef]
  19. Sokolski, M.; Sokolska, J.M.; Zymliński, R.; Biegus, J.; Banasiak, W.; Reczuch, K.; Ponikowski, P. Cardiac emergencies during the coronavirus disease 2019 pandemic in the light of the current evidence. Kardiol. Pol. 2020, 78, 818–824. [Google Scholar] [CrossRef]
  20. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef]
  21. Kubica, J.; Ostrowska, M.; Stolarek, W.; Kasprzak, M.; Grzelakowska, K.; Kryś, J.; Kubica, A.; Adamski, P.; Podhajski, P.; Navarese, E.P.; et al. Impact of COVID-19 pandemic on acute heart failure admissions and mortality: A multicentre study (COV-HF-SIRIO 6 study). ESC Heart Fail 2021. advance online publication. [Google Scholar] [CrossRef]
  22. Severino, P.; D’Amato, A.; Saglietto, A.; D’Ascenzo, F.; Marini, C.; Schiavone, M.; Ghionzoli, N.; Pirrotta, F.; Troiano, F.; Cannillo, M.; et al. Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. ESC Heart Fail. 2020, 7, 4182–4188. [Google Scholar] [CrossRef]
  23. Sokolski, M.; Gajewski, P.; Zymliński, R.; Biegus, J.; Berg, J.M.T.; Bor, W.; Braunschweig, F.; Caldeira, D.; Cuculi, F.; D’Elia, E.; et al. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. Am. J. Med. 2020, 134, 482–489. [Google Scholar] [CrossRef]
  24. Sokolski, M.; Trenson, S.; Sokolska, J.M.; D’Amario, D.; Meyer, P.; Poku, N.K.; Biering-Sørensen, T.; Lassen, M.C.H.; Skaarup, K.G.; Barge-Caballero, E.; et al. Heart failure in COVID-19: The multicentre, multinational PCHF-COVICAV registry. ESC Heart Fail. 2021. [Google Scholar] [CrossRef]
  25. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; González-Juanatey, J.R.; Harjola, V.-P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016, 37, 2129–2200. [Google Scholar] [CrossRef]
  26. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42, 3599–3726. [Google Scholar] [CrossRef]
  27. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D. Fourth Universal Definition of Myocardial Infarction (2018). J. Am. Coll. Cardiol. 2018, 72, 2231–2264. [Google Scholar] [CrossRef]
  28. Rivera-Caravaca, J.M.; Núñez-Gil, I.J.; Vivas, D.; Viana-Llamas, M.C.; Uribarri, A.; Becerra-Muñoz, V.M.; Trabattoni, D.; Rozas, I.F.; Feltes, G.; López-Pais, J.; et al. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. Eur. J. Clin. Investig. 2020, 51, e13436. [Google Scholar] [CrossRef]
  29. Tremblay, D.; Van Gerwen, M.; Alsen, M.; Thibaud, S.; Kessler, A.J.; Venugopal, S.; Makki, I.; Qin, Q.; Dharmapuri, S.; Jun, T.; et al. Impact of anticoagulation prior to COVID-19 infection: A propensity score-matched cohort study. Blood 2020, 136, 144–147. [Google Scholar] [CrossRef]
  30. Kornej, J.; Börschel, C.S.; Benjamin, E.J.; Schnabel, R.B. Epidemiology of Atrial Fibrillation in the 21st Century. Circ. Res. 2020, 127, 4–20. [Google Scholar] [CrossRef]
  31. Bavishi, A.; Patel, R.B. Addressing Comorbidities in Heart Failure. Heart Fail. Clin. 2020, 16, 441–456. [Google Scholar] [CrossRef]
  32. Tomasoni, D.; Italia, L.; Adamo, M.; Inciardi, R.M.; Lombardi, C.M.; Solomon, S.D.; Metra, M. COVID-19 and heart failure: From infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur. J. Heart Fail. 2020, 22, 957–966. [Google Scholar] [CrossRef]
  33. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020, 180, 934–943. [Google Scholar] [CrossRef]
  34. Sama, I.; Ravera, A.; Santema, B.T.; Van Goor, H.; Ter Maaten, J.M.; Cleland, J.G.F.; Rienstra, M.; Friedrich, A.W.; Samani, N.J.; Ng, L.L.; et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors. Eur. Heart J. 2020, 41, 1810–1817. [Google Scholar] [CrossRef]
  35. Varga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitzka, F.; Moch, H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020, 395, 1417–1418. [Google Scholar] [CrossRef]
  36. Schiavone, M.; Gasperetti, A.; Mancone, M.; Kaplan, A.V.; Gobbi, C.; Mascioli, G.; Busana, M.; Saguner, A.M.; Mitacchione, G.; Giacomelli, A.; et al. Redefining the Prognostic Value of High-Sensitivity Troponin in COVID-19 Patients: The Importance of Concomitant Coronary Artery Disease. J. Clin. Med. 2020, 9, 3263. [Google Scholar] [CrossRef] [PubMed]
  37. Peterson, E.; Lo, K.B.; DeJoy, R.; Salacup, G.; Pelayo, J.; Bhargav, R.; Gul, F.; Albano, J.; Azmaiparashvili, Z.; Amanullah, A.; et al. The relationship between coronary artery disease and clinical outcomes in COVID-19. Coron. Artery Dis. 2020, 32, 367–371. [Google Scholar] [CrossRef]
  38. Schiavone, M.; Gobbi, C.; Biondi-Zoccai, G.; D’Ascenzo, F.; Palazzuoli, A.; Gasperetti, A.; Mitacchione, G.; Viecca, M.; Galli, M.; Fedele, F.; et al. Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties. J. Clin. Med. 2020, 9, 1683. [Google Scholar] [CrossRef]
  39. Barman, H.A.; Atici, A.; Sahin, I.; Alici, G.; Tekin, E.A.; Baycan, F.; Ozturk, F.; Oflar, E.; Tugrul, S.; Yavuz, M.B.; et al. Prognostic significance of cardiac injury in COVID-19 patients with and without coronary artery disease. Coron. Artery Dis. 2020, 32, 359–366. [Google Scholar] [CrossRef]
  40. Sokolski, M.; Zymlinski, R.; Biegus, J.; Siwołowski, P.; Nawrocka-Millward, S.; Todd, J.; Yerramilli, M.R.; Estis, J.; A Jankowska, E.; Banasiak, W.; et al. Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. Eur. J. Heart Fail. 2017, 19, 760–767. [Google Scholar] [CrossRef]
  41. Alvarez-Garcia, J.; Lee, S.; Gupta, A.; Cagliostro, M.; Joshi, A.A.; Rivas-Lasarte, M.; Contreras, J.; Mitter, S.S.; LaRocca, G.; Tlachi, P.; et al. Prognostic Impact of Prior Heart Failure in Patients Hospitalized with COVID-19. J. Am. Coll. Cardiol. 2020, 76, 2334–2348. [Google Scholar] [CrossRef]
  42. Rey, J.R.; Caro-Codón, J.; Rosillo, S.O.; Iniesta, Á.M.; Castrejón-Castrejón, S.; Marco-Clement, I.; Martín-Polo, L.; Merino-Argos, C.; Rodríguez-Sotelo, L.; García-Veas, J.M.; et al. Heart failure in COVID-19 patients: Prevalence, incidence and prognostic implications. Eur. J. Heart. Fail. 2020, 22, 2205–2215. [Google Scholar] [CrossRef]
  43. Rumery, K.; Seo, A.; Jiang, L.; Choudhary, G.; Shah, N.R.; Rudolph, J.L.; Wu, W.; Erqou, S. Outcomes of coronavirus disease-2019 among veterans with pre-existing diagnosis of heart failure. ESC Heart Fail. 2021, 8, 2338–2344. [Google Scholar] [CrossRef] [PubMed]
  44. Anyu, A.T.; Badawy, L.; Cannata, A.; Bromage, D.I.; Rind, I.A.; Albarjas, M.; Piper, S.; Shah, A.M.; McDonagh, T.A. Long-term outcomes after heart failure hospitalization during the COVID-19 pandemic: A multisite report from heart failure referral centers in London. ESC Heart Fail. 2021. [Google Scholar] [CrossRef]
Figure 1. The all-cause mortality in the studied groups.
Figure 1. The all-cause mortality in the studied groups.
Jcm 11 00241 g001
Figure 2. Kaplan–Meier curves for all-cause mortality in studied groups.
Figure 2. Kaplan–Meier curves for all-cause mortality in studied groups.
Jcm 11 00241 g002
Figure 3. Forest plots for age, sex, and age/sex categories in patients with a history of heart failure vs. without history of heart failure.
Figure 3. Forest plots for age, sex, and age/sex categories in patients with a history of heart failure vs. without history of heart failure.
Jcm 11 00241 g003
Table 1. Baseline demographics, clinical characteristics, comorbidities, and related treatment in the studied cohorts.
Table 1. Baseline demographics, clinical characteristics, comorbidities, and related treatment in the studied cohorts.
Variables, UnitsHF Group
n = 255
Non-HF Group
n = 1929
pAvailable Data, n (%)
Age, years75 ± 1258 ± 19<0.0012184 (100)
Age ≥ 70 years, n (%)169 (66)571 (30)<0.0012184 (100)
Male gender, n (%)144 (57)938 (49)0.0222184 (100)
Body mass index, kg/m228 ± 628 ± 50.950554 (25)
Hypertension, n (%)215 (84)807 (42)<0.0012184 (100)
Diabetes mellitus, n (%)122 (48)394 (20)<0.0012182 (100)
Atrial fibrillation/flutter, n (%)134 (53)156 (8)<0.0012184 (100)
Previous coronary revascularization, n (%)93 (37)61 (3)<0.0012184 (100)
Previous myocardial infarction, n (%)92 (36)99 (5)<0.0012184 (100)
Significant valvular heart disease or previous valve heart surgery, n (%) 64 (25)32 (2)<0.0012184 (100)
Peripheral artery disease, n (%)43 (17)57 (3)<0.0012184 (100)
Previous stroke/transient ischemic attack, n (%)53 (21)111 (6)<0.0012184 (100)
Chronic kidney disease or/and hemodialysis, n (%)92 (36)139 (7)<0.0012184 (100)
Asthma, n (%)10 (4)75 (4)0.9792184 (100)
Chronic obstructive pulmonary disease, n (%)29 (11)46 (2)<0.0012184 (100)
Cigarette smoking (previous or current), n (%)55 (22)138 (7)<0.0012180 (100)
Sleep apnea syndrome, n (%)7 (3)9 (1)<0.0012184 (100)
Chronic liver disease, n (%)15 (6)59 (3)0.0312183 (100)
Thyroid disease, n (%)33 (13)/7 (3)175 (9)/14 (1)0.0012184 (100)
Dementia, n (%)50 (20)82 (4.3)<0.0012184 (100)
Malignancy, n (%)29 (11)156 (8)0.0992184 (100)
Transplant recipients, n (%)7 (3)26 (1)0.1482184 (100)
Treatment Applied before Hospitalization
Angiotensin-converting enzyme inhibitors, n (%)104 (41)248 (13)<0.0012184 (100)
Angiotensin receptor blockers, n (%)24 (9)120 (6)0.0732184 (100)
Mineralocorticoid receptor antagonists, n (%)56 (22)44 (2)<0.0012184 (100)
β-blockers, n (%)153 (60)380 (20)<0.0012184 (100)
Ivabradine, n (%)1 (0.4)2 (0.1)0.7882184 (100)
Digitalis glycoside, n (%)10 (4)9 (1)<0.0012184 (100)
Calcium blockers (nondihydropyridine), n (%)11 (4)27 (1)0.0022184 (100)
Calcium blockers (dihydropyridine), n (%)65 (26)196 (10)<0.0012184 (100)
α-adrenergic blockers, n (%)39 (15)79 (4)<0.0012184 (100)
Thiazide or thiazidelike diuretics, n (%)28 (11)122 (6)0.0092184 (100)
Loop diuretics, n (%)100 (39)85 (4)<0.0012184 (100)
Statins, n (%)123 (48)227 (12)<0.0012184 (100)
Acetylsalicylic acid, n (%)76 (30)182 (9)<0.0012184 (100)
Second antiplatelet drug, n (%)20 (8)19 (1)<0.0012184 (100)
Low-molecular-weight heparin, n (%)28 (11)113 (6)0.0032184 (100)
Vitamin K antagonists, n (%)22 (9)25 (1)<0.0012184 (100)
Direct oral anticoagulants, n (%)55 (22)52 (3)<0.0012184 (100)
Insulin, n (%)39 (15)92 (5)<0.0012184 (100)
Metformin, n (%)52 (20)170 (9)<0.0012184 (100)
Sodium–glucose cotransporter-2 inhibitors, n (%)11 (4)16 (1)<0.0012184 (100)
Oral antidiabetics other than mentioned above, n (%)30 (12)59 (3)<0.0012184 (100)
Oral corticosteroid, n (%)9 (4)83 (4)0.6802184 (100)
Immunosuppression other than corticosteroid, n (%)8 (3)65 (3)0.9932184 (100)
Home oxygen therapy or ventilation n (%)4 (1.6)4 (0.2)0.0052184 (100)
Hemodialysis, n (%)21 (8)37 (2)<0.0012184 (100)
Table 2. Patient-reported symptoms, vital signs, and abnormalities measured during physical examination at hospital admission in the studied cohorts.
Table 2. Patient-reported symptoms, vital signs, and abnormalities measured during physical examination at hospital admission in the studied cohorts.
Variables, UnitsHF Group
n = 255
Non-HF Group
n = 1929
pAvailable Data, n (%)
Patient-Reported Symptoms
Cough, n (%)67 (26)581 (30)0.2342184 (100)
Dyspnea, n (%)144 (57)777 (40)<0.0012184 (100)
Chest pain, n (%)29 (11)134 (7)0.0162184 (100)
Hemoptysis, n (%)4 (2)11 (1)0.1582184 (100)
Smell dysfunction, n (%)4 (2)72 (4)0.1122184 (100)
Taste dysfunction, n (%)5 (2)61 (3)0.3912184 (100)
Abdominal pain, n (%)16 (6)131 (7)0.8602184 (100)
Diarrhea, n (%)16 (6)111 (6)0.8482184 (100)
Vomiting, n (%)11 (4)87 (4)0.8872184 (100)
Measured Vital Signs
Body temperature, °C36.9 ± 0.937.0 ± 0.90.1821186 (54)
Heart rate, beats/minute85 ± 1986 ± 160.3641672 (77)
Systolic blood pressure, mmHg133 ± 26132 ± 220.4941169 (76)
SpO2 on room air, %90 ± 1092 ± 80.0011263 (58)
SpO2 on oxygen supplementation, %94 ± 695 ± 60.420824 (38)
Abnormalities Detected during Physical Examination
Wheezing, n (%)59 (23)160 (8)<0.0012184 (100)
Pulmonary congestion, n (%)85 (33)282 (15)<0.0012184 (100)
Peripheral oedema, n (%)58 (23)131 (7)<0.0012184 (100)
Table 3. Laboratory parameters measured on admission in the studied cohorts.
Table 3. Laboratory parameters measured on admission in the studied cohorts.
Variables, UnitsHF Group
n = 255
Non-HF Group
n = 1929
pAvailable Data,n (%)
Leukocytes, 103/µL7.7 (5.8–10.6)7.3 (5.3–10.3)0.0402050 (94)
Lymphocytes, 103/µL0.9 (0.6–1.4)1.0 (0.7–1.4)0.0071296 (59)
Neutrophils, 103/µL5.7 (3.8–9.1)5.5 (3.4–8.2)0.0581299 (59)
Hemoglobin, g/dL12.0 ± 2.413.1 ± 2.2<0.0012050 (94)
Electrolytes, Inflammatory
Sodium, mmol/L138 ± 6138 ± 50.9582032 (93)
Potassium, mmol/L4.3 ± 0.84.1 ± 0.6<0.0012039 (93)
CRP, mg/L46 (13–102)49 (13–117)0.6862020 (92)
Procalcitonin, ng/mL0.15 (0.06–0.57)0.08 (0.04–0.26)<0.0011475 (68)
IL-6, pg/mL28 (11–59)16 (6–44)0.002702 (32)
Ferritin, ng/mL557 (197–1212)602 (297–1150)0.309969 (44)
Urea, mg/dL64 (44–101)36 (25–57)<0.0011859 (85)
eGFR, ml/min/1.73 m253 ± 3178 ± 34<0.0011958 (90)
Albumin, g/L3.0 ± 0.63.1 ± 0.60.132665 (30)
Uric acid, mg/dL6.7 (5.4–9.2)5.2 (3.9–6.7)<0.001623 (29)
Bilirubin, mg/dL0.7 (0.5–1.1)0.6 (0.5–0.8)<0.0011408 (64)
GGTP, U/L43 (24–97)43 (24–86)0.9161352 (62)
Cardiac Biomarkers
NT-proBNP, pg/mL6496 (2255–15,881)551 (160–2441)<0.001379 (17)
Troponin I, ng/L55 (23–157)11 (4–36)<0.0011174 (64)
Table 4. In-hospital course and therapies applied during the hospitalization in the studied cohorts.
Table 4. In-hospital course and therapies applied during the hospitalization in the studied cohorts.
Variables, UnitsHF Group
n = 255
Non-HF Group
n = 1929
pAvailable Data, n (%)
In-hospital Course
Duration of hospitalization, days13 (4–21)9 (2–15)<0.0012184 (100)
Admission at intensive care unit, n (%)33 (13)181 (9)0.0922184 (100)
Shock, n (%)38 (15)150 (8)<0.0012184 (100)
Myocardial infarction, n (%)10 (4)16 (1)<0.0012184 (100)
Thromboembolic disease, n (%)10 (4)59 (3)0.4592184 (100)
Stroke, n (%)7 (3)37 (2)0.3772184 (100)
Acute HF, n (%)53 (21)23 (1)<0.0012184 (100)
Applied Treatment and Procedures
Passive oxygen therapy, n (%)109 (43)654 (34)0.0062181 (100)
Non-invasive ventilation, n (%)37 (15)136 (7)<0.0012181 (100)
Mechanical ventilation, n (%)33 (13)182 (9)0.0982184 (100)
Duration of mechanical ventilation, days8 (2–15)9 (4–17)0.176197 (9)
Therapy with catecholamines, n (%)45 (18)173 (9)<0.0012184 (100)
Therapy with loop diuretics, n (%)104 (41)229 (12)<0.0012184 (100)
Extracorporeal membrane oxygenation, n (%)1 (0.4)22 (1.1)0.4392184 (100)
Coronary angiography, n (%)12 (5)18 (1)<0.0012184 (100)
Coronary revascularization, n (%)11 (4)20 (1)0.0012184 (100)
Hemodialysis, n (%)17 (7)55 (3)0.0032184 (100)
Amiodarone, n (%)17 (7)39 (2)<0.0012184 (100)
Nitroglycerine (i.v.), n (%)7 (3)12 (1)0.0022184 (100)
Low-molecular-weight heparin, n (%)160 (63)1105 (57)0.1112184 (100)
Unfractionated heparin, n (%)12 (5)110 (6)0.6132184 (100)
Direct oral anticoagulants, n (%)29 (11)6 (3)<0.0012184 (100)
Vitamin K antagonists, n (%), n (%)5 (2)15 (1)0.1302184 (100)
Acetylsalicylic acid, n (%)81 (32)285 (15)<0.0012184 (100)
Thrombolytic therapy, n (%)1 (0.4)13 (0.7)0.9112184 (100)
Systemic corticosteroid, n (%)129 (51)967 (50)0.9432184 (100)
Convalescent plasma, n (%)33 (13)206 (11)0.3272184 (100)
Hydroxychloroquine/chloroquine, n (%)0 (0)9 (1)0.5672184 (100)
Tocilizumab, n (%)1 (0.4)24 (1.2)0.3742184 (100)
Remdesivir, n (%)38 (15)305 (16)0.7772184 (100)
Antibiotic, n (%)168 (66)1073 (56)0.0022184 (100)
Prone positioning, n (%)22 (9)182 (9)0.7612184 (100)
Table 5. Predictors of acute HF during hospitalization in patients with COVID-19.
Table 5. Predictors of acute HF during hospitalization in patients with COVID-19.
Variables, UnitsUnivariable ModelsMultivariable Model
OR (95% CI)OR (95% CI)p
Age, per 5 years1.39 (1.27–1.51)1.23 (1.11–1.36)<0.001
Arterial hypertension, yes/no3.82 (2.24–6.54)--
Diabetes mellitus, yes/no2.73 (1.72–4.34)--
History of heart failure, yes/no21.74 (13.05–36.23)11.42 (6.49–20.10)<0.001
History of myocardial infarction, yes/no6.12 (3.71–10.10)1.67 (0.95–2.94)0.074
Atrial fibrillation/flutter, yes/no5.52 (3.45–8.86)--
Valvular heart disease, yes/no5.58 (3.00–10.38)--
Peripheral artery disease, yes/no3.84 (1.96–7.53)--
Chronic kidney disease, yes/no4.53 (2.75–7.46)--
Chi2 = 171, p < 0.001. OR: odds ratio, CI: confidence interval.
Table 6. Predictors of 3-month mortality—univariable model.
Table 6. Predictors of 3-month mortality—univariable model.
VariablesUnitsUnivariable Model
HR (95% CI)p
Age5 years1.31 (1.27–1.35)<0.001
History of heart failureyes/no2.95 (2.42–3.59)<0.001
GenderMale1.53 (1.29–1.82)<0.001
Diabetes mellitusyes/no1.89 (1.57–2.26)<0.001
Arterial hypertensionyes/no2.16 (1.82–2.58)<0.001
Chronic obstructive pulmonary diseaseyes/no2.59 (1.87–3.59)<0.001
Previous stroke/transient ischemic attackyes/no1.80 (1.39–2.33)<0.001
Chronic kidney diseaseyes/no2.43 (1.97–3.00)<0.001
Malignancyyes/no2.42 (1.93–3.03)<0.001
C-reactive proteinLn 1 mg/L1.49 (1.39–1.60)<0.001
Hemoglobin1 g/dL0.87 (0.84–0.90)<0.001
Table 7. Predictors of 3-month mortality—multivariable model.
Table 7. Predictors of 3-month mortality—multivariable model.
VariablesUnitsMultivariable Models
HR (95% CI)Wald’s StatisticspChi2 (p)
Age5 years1.29 (1.25–1.33)269<0.001416 (<0.001)
History of heart failureyes/no1.54 (1.25–1.88)17< 0.001
GenderMale1.53 (1.29–1.82)20<0.001114 (<0.001)
History of heart failureyes/no2.86 (2.35–3.48)109< 0.001
Age5 years1.32 (1.28–1.37)283< 0.001462 (<0.001)
GenderMale1.82 (1.53–2.17)45< 0.001
History of heart failureyes/no1.48 (1.21–1.81)14< 0.001
Age5 years1.32 (1.27–1.36)250< 0.001504 (<0.001)
GenderMale1.71 (1.43–2.04)36< 0.001
Diabetes mellitusyes/no1.20 (0.99–1.44)3.60.059
Arterial hypertensionyes/no0.91 (0.75–1.11)0.90.346
COPDyes/no1.40 (1.00–1.96)3.90.049
Previous stroke/TIAyes/no0.93 (0.71–1.21)0.30.579
Chronic kidney diseaseyes/no1.40 (1.11–1.75)8.10.004
Malignancyyes/no1.87 (1.49–2.35)29<0.001
History of heart failureyes/no1.31 (1.05–1.63)5.780.016
Age5 years1.30 (1.26–1.35)204<0.001571 (<0.001)
GenderMale1.59 (1.33–1.91)26<0.001
Diabetes mellitusyes/no1.12 (0.92–1.35)1.30.252
Arterial hypertensionyes/no0.93 (0.76–1.12)0.60.433
COPDyes/no1.38 (0.98–1.93)3.40.065
Previous stroke/TIAyes/no0.98 (0.74–1.29)0.030.87
Chronic kidney diseaseyes/no1.30 (1.03–1.65)4.70.03
Malignancyyes/no1.86 (1.47–2.35)27<0.001
CRPLn 1 mg/L1.42 (1.32–1.52)93<0.001
Hemoglobin1 g/dL0.94 (0.91–0.98)9.20.002
History of heart failureyes/no1.35 (1.08–1.69)70.008
HR: hazard ratio; CI: confidence interval; COPD: chronic obstructive pulmonary disease; TIA: transient ischemic attack; CKD: chronic kidney disease; CRP: C-reactive protein; Ln: natural logarithm.
Table 8. Outcomes investigated in patients according to left ventricular ejection fraction.
Table 8. Outcomes investigated in patients according to left ventricular ejection fraction.
Variables, UnitsHFrEFHFmrEFHFpEFp
In-hospital mortality, n (%)18 (44)8 (42)14 (20)0.016
3-month mortality, n (%)26 (63)13 (68)19 (27)<0.001
6-month mortality, n (%)26 (74)13 (76)25 (42)0.002
HFrEF: heart failure with reduced ejection fraction; HFmrEF heart failure with mildly reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction.
Table 9. Outcomes investigated in patients admitted to intensive care unit vs. those without intensive care unit stay.
Table 9. Outcomes investigated in patients admitted to intensive care unit vs. those without intensive care unit stay.
Variables, UnitsIntensive Care
Unit Stay
Without Intensive Care Unit Stayp
In-hospital mortality, n (%)118 (55)208 (11)<0.001
3-month mortality, n (%)132 (62)414 (21)<0.001
6-month mortality, n (%)134 (71)444 (34)<0.001
Table 10. Outcomes investigated in patients admitted to intensive care unit according to history of heart failure.
Table 10. Outcomes investigated in patients admitted to intensive care unit according to history of heart failure.
Variables, UnitsHF GroupNon-HF Groupp
In-hospital mortality, n (%)25 (76)93 (51)0.009
3-month mortality, n (%)27 (82)105 (58)0.010
6-month mortality, n (%)27 (87)17 (68)0.033
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Back to TopTop